Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study



Cahn, Avivit, Raz, Itamar, Bonaca, Marc, Mosenzon, Ofri, Murphy, Sabina A, Yanuv, Ilan, Rozenberg, Aliza, Wilding, John PH ORCID: 0000-0003-2839-8404, Bhatt, Deepak L, McGuire, Darren K
et al (show 9 more authors) (2020) Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. DIABETES OBESITY & METABOLISM, 22 (8). 1357 - 1368.

[img] Text
Dapagliflozin safety DOM revision2 clean.docx - Accepted Version

Download (805kB)
Item Type: Article
Uncontrolled Keywords: acute kidney injury, dapagliflozin, diabetic ketoacidosis, fractures, genital infections, hypoglycaemia, malignancy, safety, SGLT2 inhibitor, urinary tract infections, volume depletion
Depositing User: Symplectic Admin
Date Deposited: 07 Oct 2020 09:14
Last Modified: 20 Aug 2022 05:11
DOI: 10.1111/dom.14041
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3103679